In 32 adults with cutaneous lichen planus, 12 weeks of baricitinib cut LiPADI activity scores more than hydroxychloroquine (mean 14.20 to 1.07 vs 12.18 to 5.27; P=0.03), with less itch; PGA did not differ (P=0.38). No major adverse events.
RCTn = 32
Kargar et al. Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial